Guanfacine (Tenex)

A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.

Also Known As:

Tenex; BS-100-141; Estulic; Guanfacine Hydrochloride; Guanfacine Monohydrochloride; Lon798; BS 100 141; BS100141; Hydrochloride, Guanfacine; Monohydrochloride, Guanfacine; Benzeneacetamide, N-(aminoiminomethyl)-2,6-dichloro-

Networked: 492 relevant articles (84 outcomes, 97 trials/studies)

Relationship Network

Drug Context: Research Results

Organic Chemicals: 133
- Carboxylic Acids: 973
  - Carbocyclic Acids
    - Phenylacetates: 3
      - Guanfacine: 492
- Amidines: 14
  - Guanidines: 29
    - Guanfacine: 492

Experts

1.	Sikirica, Vanja: 16 articles (11/2017 - 05/2012)
2.	Lyne, Andrew: 15 articles (01/2016 - 04/2007)
3.	Newcorn, Jeffrey H: 11 articles (01/2020 - 01/2003)
4.	Arnsten, Amy F T: 10 articles (12/2020 - 07/2002)
5.	Robertson, Brigitte: 9 articles (01/2020 - 11/2012)
6.	Huss, Michael: 8 articles (01/2020 - 12/2014)
7.	McCracken, James T: 8 articles (01/2018 - 02/2010)
8.	Connor, Daniel F: 7 articles (01/2020 - 09/2010)
9.	McBurnett, Keith: 7 articles (01/2019 - 01/2008)
10.	Scahill, Lawrence: 7 articles (01/2018 - 11/2005)

Related Diseases

1.	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 02/28/2016 - "The purpose of this study was to examine the efficacy of an extended release guanfacine hydrochloride supplement relative to a placebo supplement in adults (19-62) with ADHD and a sub-optimal response to a stimulant-only treatment program. " 01/01/1995 - "This preliminary study indicates that guanfacine is a beneficial and useful treatment of ADHD, reducing hyperactive behaviors and enabling greater attentional ability with minimal side effects. " 01/01/2023 - "Guanfacine was significantly more effective in treating ADHD (Risk Ratio [RR] 1.78, 95% CI: 1.59-2.01). " 09/01/2010 - "A significantly greater reduction in ADHD-RS-IV total score from baseline to endpoint was also seen in the guanfacine-treated group compared with the placebo group (23.8 vs 11.5, respectively; p < 0.001; effect size = 0.92). " 01/01/2008 - "All groups of children taking guanfacine extended release showed significant improvement on hyperactivity/impulsivity and inattentiveness subscales of the Attention-Deficit/Hyperactivity Disorder Rating Scale IV, Clinical Global Impression of Improvement, Parent's Global Assessment, Conners' Parent Rating Scale-Revised: Short Form, and Conners' Teacher Rating Scale-Revised: Short Form assessments compared with placebo. "
2.	Hypertension (High Blood Pressure) 08/01/1982 - "This study demonstrated the efficacy of guanfacine monotherapy in hypertension and suggests that the normalization rate of blood pressure levels does not further increase with daily doses higher than 4 mg." 01/01/1989 - "Guanfacine monotherapy was effective in 75% of patients with moderate hypertension (using low doses 1-3 mg/day). " 07/01/1982 - "[Efficacy of guanfacine in the treatment of arterial hypertension]." 11/01/2014 - "QTc (QTcF and QTcNi) was prolonged at both therapeutic (4 mg) and supratherapeutic (8 mg) doses of a thorough QT study even though guanfacine has had a safe clinical history of over 3 million prescriptions for the treatment of hypertension. " 01/01/1987 - "In another study, the authors administered guanfacine to 30 I- and II- type diabetics with essential, primarily stage I, hypertension. "
3.	Tics (Tic) 03/13/2017 - "Extended-release guanfacine enables the professional to treat situations that are poorly covered by stimulants, such as children with irritability and tics, with a significant profile characterised by moderate efficacy and good tolerability and safety. " 07/01/2001 - "Tic severity decreased by 31% in the guanfacine group, compared to 0% in the placebo group. " 09/01/1995 - "In addition, guanfacine caused a significant decrease in severity of motor (p < .02) and phonic (p < .02) tics as measured by the TSSR and the YGTSS, respectively. " 07/01/1997 - "It may be reasonable to initiate a trial of guanfacine in a patient who has not responded to or cannot tolerate other agents due to adverse effects or drug dependence, or in a patient who develops motor tics. " 11/01/2017 - "Extended-Release Guanfacine Does Not Show a Large Effect on Tic Severity in Children with Chronic Tic Disorders."
4.	Essential Hypertension 03/28/1986 - "Study 2 was a double-blind, randomized, parallel clinical study with placebo control with 42 patients with mild essential hypertension treated with either guanfacine (1 mg/day) or matching placebo at bedtime for 8 weeks. " 03/28/1986 - "Study 1 was a double-blind, randomized, parallel trial with a placebo control with 26 patients with mild essential hypertension treated with 1-mg guanfacine or matching placebo daily at bedtime for 8 weeks. " 01/01/1996 - "Estulic, a hypotensive drug of a central mechanism of action, has been tried for effect on hemodynamics, coronary circulation and platelet functional activity in 30 patients with essential hypertension. " 01/04/1993 - "The subject of the work is to assess the clinical parameters and diastolic function in patients with mild or moderate essential hypertension after 5-month treatment with guanfacine 0.5-3 mg/day, mean 1.7 mg. In the group there were 8 women and 8 men, mean age 53.7 +/- 7.6. " 02/01/1990 - "The schedule of estulic administration for stage I-II essential hypertension in more effective at lower doses and better tolerance when adjusted to circadian variations in arterial pressure. "
5.	Tic Disorders (Tic Disorder) 01/01/2021 - "Guanfacine is a central alpha-2 agonist often prescribed for Attention-deficit hyperactive disorder as well as tic disorder, with a usual dose of 1-4 mg per day. " 07/01/2001 - "Subjects from a specialty tic disorders clinic were randomly assigned to receive 8 weeks of treatment with guanfacine or placebo under double-blind conditions. " 07/01/2001 - "Guanfacine appears to be a safe and effective treatment for children with tic disorders and ADHD." 11/01/2005 - "Results of this open-label study add to the growing data base on the safety and efficacy of guanfacine in children with ADHD and tic disorders." 11/01/2017 - "To evaluate the tolerability, safety, and preliminary efficacy of extended-release guanfacine in children with chronic tic disorders, including Tourette's disorder (collectively referred to as CTD). "

Related Drugs and Biologics

1.	Clonidine (ST 155)
2.	Atomoxetine Hydrochloride (Strattera)
3.	Methylphenidate (Ritalin)
4.	Antihypertensive Agents (Antihypertensives)
5.	Methyldopa (Aldomet)
6.	Risperidone (Risperdal Consta)
7.	Aripiprazole (Abilify)
8.	Desipramine (Pertofrane)
9.	Amphetamine (Amfetamine)
10.	Amphetamines

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Injections
4.	Secondary Prevention
5.	Tenotomy